221 related articles for article (PubMed ID: 35957899)
1. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.
Zhou T; Mahn R; Möhring C; Sadeghlar F; Meyer C; Toma M; Kreppel B; Essler M; Glowka T; Matthaei H; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Front Oncol; 2022; 12():933943. PubMed ID: 35957899
[TBL] [Abstract][Full Text] [Related]
2. Olaparib and Pembrolizumab Treatment for
Xiong F; Gong J; Wang Q
Onco Targets Ther; 2020; 13():6385-6391. PubMed ID: 32753881
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
4. Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.
Costa BA; Tallón de Lara P; Park W; Keane F; Harding JJ; Khalil DN
Oncol Res Treat; 2023; 46(5):211-215. PubMed ID: 36882017
[TBL] [Abstract][Full Text] [Related]
5. Durable response to first-line PARP inhibition in
Smith JT; Sama S; Florou V; Nevala-Plagemann C; Garrido-Laguna I
J Gastrointest Oncol; 2023 Dec; 14(6):2637-2643. PubMed ID: 38196540
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report.
Chen Z; Wang K; Zhao L; Gong L
Front Oncol; 2023; 13():1190100. PubMed ID: 37260982
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
8. Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review.
Tan S; Yu J; Huang Q; Zhou N; Xiong X; Gou H
Front Pharmacol; 2022; 13():1037646. PubMed ID: 36518664
[No Abstract] [Full Text] [Related]
9. Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
Cheng Y; Zhang J; Qin SK; Hua HQ
Onco Targets Ther; 2018; 11():5957-5962. PubMed ID: 30271179
[TBL] [Abstract][Full Text] [Related]
10. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
11. Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.
Artzenroth JC; Tintelnot J; Haag GM; Gökkurt E; Steffens J; Stein A
Oncol Res Treat; 2023; 46(7-8):320-325. PubMed ID: 37231946
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
15. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
[TBL] [Abstract][Full Text] [Related]
16. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
Kawanishi M; Fujita M; Karasawa K
Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
18. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
19. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
[TBL] [Abstract][Full Text] [Related]
20. Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature.
He MY; Yan FF; Cen KL; Shen P
World J Clin Cases; 2022 Nov; 10(32):11889-11897. PubMed ID: 36405269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]